UNSPSC 51431701: Benazepril

This classification denotes an ace inhibitor with the molecular formula C24H28N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UDM7Q7QWP8, chemically known as 1h-1-benzazepine-1-acetic acid, 3-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (s-(r*,r*))- but generally known as benazepril, which bears US NIH Compound Identifier 5362124. Benazepril most often comes in base and hydrochloride forms.

UNSPSC 51431701 Benazepril is a Commodity-level code for a single pharmaceutical product—an ACE inhibitor antihypertensive agent—that state and local governments procure primarily through emergency medical services, public health programs, and institutional pharmacy benefit arrangements. Recent solicitations show procurement focused on emergency medications supplied to fire rescue services and through cooperative purchasing vehicles serving multiple state agencies and jurisdictions. The buying mix spans municipal fire departments, state health commissions, and multistate cooperative purchasing alliances; the City of Tampa's Fire Rescue and the Texas Health and Human Services Commission appear as recent solicitors, with MMCAP (Minnesota Multistate Cooperative Purchasing Alliance) acting as an administrative vehicle for multi-state and local government pharmaceutical procurement. The code's activity reflects institutional demand for pharmaceuticals where price, supply chain compliance (cGMP, DSCSA, FDA certification), and delivery speed are primary selection drivers.

Recent opportunities cluster in Florida and Minnesota, with Texas state-level activity signaling broader regional interest. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications (including related emergency agents such as Labetalol, Epinephrine, Adenosine, and Diltiazem) due April 8, 2026, with an estimated contract value of $40,000 and a Small Local Business Enterprise set-aside with a 5 percent bid discount capped at $10,000; the contract runs one year from award with two optional one-year renewals plus up to three unilateral 30-day extensions. The Texas HHS Commission issued RFI HHS0017013 in late March 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling preliminary state-level interest in alternative pharmacy procurement models before formal RFP issuance. MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, effective July 1, 2026) establishes multi-year contracts across participating state and local facilities in Minnesota and Oregon, with pricing weighted at 75 percent of evaluation and mandatory compliance with cGMP, DSCSA, FDA requirements, and authorized-wholesaler distribution through AmerisourceBergen, Cardinal Health, and Morris & Dickson.